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first and second line therapy for advanced NSCLC patients with EGFR mutation by 
China guideline for treatment of primary lung cancer. This study aims to system-
atically evaluate cost-effectiveness of geftinib in China. Methods: A systematic 
review of cost-effectiveness of geftinib in China was conducted. We searched for 
Chinese literatures in “CNKI”, “Wanfang data”, and “VIP.com”. Search pattern was 
“gefitinb” AND “cost or economic or expense” in abstract. Publication deadline was 
May 31th, 2015. Cost analysis (CA), cost-effectiveness analysis (CEA), cost-utility 
analysis (CUA), and cost-benefit analysis of gefitinib were included. NoteExpress 
2.7 was used for literature management. Results: We retrieved abstracts of 39, 42 
and 20 from CNKI, Wanfang and VIP respectively. Then 59 abstracts were selected 
to conduct abstract analysis after deleting duplications, followed by 15 selected to 
full-text analysis. At last, 7 studies were included. For first line treatment compari-
son, 1 CUA evaluating gefitinib and chemotherapy (paclitaxel+carboplatin) shows 
geftinib dominates the chemotherapy with an ICER of ¥-13499.7/QALY. For second 
line comparison, 2 CAs show costs of geftinib are much lower than comparators, 3 
CEAs show gefitinib is cost effective compared to erlotinib with much lower cost-
effectiveness ratios, and 1 CEA shows docetaxel is dominated by gefitinib, which 
has much lower costs(¥23022 vs. ¥24390) and higher objective response rate(26.90% 
vs. 10.30%). ConClusions: Our systematic review demonstrates that Gefitinib is 
cost effective in both first and second line treatment of NSCLC in a Chinese setting.
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objeCtives: The treatment landscape of metastatic castration resistant prostate 
cancer (mCRPC) has changed with the introduction of novel agents. As little is 
known about their cost-effectiveness, this study investigates the cost-effectiveness 
of radium-223 versus cabazitaxel, abiraterone and enzalutamide in Dutch mCRPC 
patients previously treated with docetaxel. Methods: A cost-effectiveness analy-
sis was conducted utilizing efficacy, symptomatic skeletal event (SSE) and safety 
data obtained from indirect treatment comparisons. As SSE data are unavailable 
for cabazitaxel, we conservatively assumed these to be identical to radium-223. A 
Markov model combined these clinical inputs with Dutch-specific resource use 
and costs for mCRPC treatment. Total quality-adjusted-life-years (QALYs) and costs 
were calculated over a 5-year horizon. Analyses were performed from a societal 
perspective. Results: Radium-223 is associated with € 4,535 and € 5,905 lower 
lifetime costs and a difference of -0.004 and 0.02 QALYs compared to cabazitaxel 
and abiraterone, respectively. Sensitivity analyses reveal a 59% (78%) chance of 
radium-223 being cost-effective compared to cabazitaxel (abiraterone) at a € 80,000 
willingness to pay (WTP) threshold, the informal Dutch threshold. Compared to 
enzalutamide, radium-223 is associated with a slightly lower QALY gain (-0.06) and 
€ 7,255 lower lifetime costs, resulting in only a 19% chance of enzalutamide being 
cost-effective compared to radium-223 at a € 80,000 WTP threshold. Sensitivity 
analyses reveal a 74%, 80% and 78% chance of radium-223 being cost-saving com-
pared to cabazitaxel, abiraterone and enzalutamide, respectively.Radium-223’s lower 
lifetime costs compared to abiraterone and enzalutamide are driven by less drug 
costs and prevention of expensive SSE’s. Compared to cabazitaxel, radium-223’s 
savings are driven by fewer costs of the drug, administration and adverse event 
treatment. ConClusions: Our model shows that while QALY gains are in the same 
ballpark (a maximum absolute difference of 0.06 QALY), radium-223 is a cost-saving 
treatment compared to cabazitaxel, abiraterone and enzalutamide in Dutch mCRPC 
patients previously treated with docetaxel.
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objeCtives: Febrile neutropenia (FN) is a common side effect of systemic chemo-
therapy associated with significant morbidity, mortality, detrimental quality of life 
and high costs. Most FN events occur in the first cycle. Guidelines recommend 
the prophylactic use of a recombinant human granulocyte colony-stimulating fac-
tor (G-CSF) in patients receiving chemotherapy if risk of FN ≥ 20%. We aimed to 
assess the cost-effectiveness of different G-CSF primary prophylactic regimens in 
Mexico. Methods: A decision model allowed comparison of expected costs and 
outcomes after three competing interventions as prophylaxis: Pegfilgrastim 6mg 
once (PegFGT); filgrastim 300μ g daily during 6 days (FGT-6d) or 3 days (FGT-3d). 
Time-horizon was 21 days (i.e., first cycle). Direct medical costs comprising acquisi-
tion of G-CSF plus ambulatory/inpatient medical care derived from FN were ana-
lyzed under the perspective of Mexican public health system and expressed in 
2015 dollars (USD). Clinical outcomes included frequency of FN events and deaths 
attributable to FN. Published literature and indirect treatment comparisons were 
used for estimating the effectiveness for each intervention. Costs parameters were 
based on local sources. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: PegFGT was the least costly strategy (USD$1,473) leading to 
overall savings of USD$103 (6.6%) and USD$327 (18.2%) when compared to FGT-6d 
and FGT-3d, respectively. The expected number of FN events and deaths caused by 
FN were also lower with PegFGT (99; 11) than with FGT-6d (241; 26) or FGT-3d (285; 31), 
leading to a lower cost of treatment. Based on the cost-effectiveness results, PegFGT 
was the least costly option in around 89% of the simulations generated through 
probabilistic sensitivity analysis. ConClusions: A single dose of pegfilgrastim 
given instead of administering daily doses of filgrastim for 3 or 6 days leads to better 
NSCLC with Del 19 mutation increased quality-adjusted life years (QALY) by 0,354, 
0,665 and 0,670 QALY and overall survival by 0,61, 0,99 and 0,95 years in compari-
son with erlotinib, gefitinib and combination cisplatin/pemetrexed respectively. 
The total costs of therapy for compared drugs were: afatinib – 1 917 425 rub., 
erlotinib – 1 544 852 rub., gefitinib – 1 205 353 rub. and cisplatin/pemetrexed – 1 
203 865 rub. The ICERs were 1 052 934, 1 067 116 и 1 064 708 rubles in comparison 
with erlotinib, gefitinib and combination cisplatin/ pemetrexed respectively per 
QALY. ConClusions: Afatinib was demonstrated to have the highest efficiency 
in terms of overall survival and QALY. Direct costs associated with afatinib were 
the highest because of afatinib superior efficiency. Afatinib was shown to be 
the cost-effective strategy in 1st-line treatment of metastatic NSCLC with Del 
19 gene mutation as willingness to pay threshold (1 455 741,77 rubles) was not 
exceeded.
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objeCtives: Ministry of Health, Labour and Welfare of Japan aims for the intro-
duction of Health Technology Assessment in FY2016. Compared to foreign coun-
tries, a lack of resources for conducting the analysis has been pointed out in 
Japan. However, pharmaceutical and medical device industries are urged to seek 
practical approaches utilizing best available resources. The objective of this study 
was to review articles for cost-effectiveness studies of multiple myeloma (MM) 
and to evaluate analytical approaches that can be applied to Japanese environ-
ment. Methods: The literature search was conducted in MEDLINE and JDream 
III. Inclusion criteria are studies of 1) chemotherapy for MM, 2) cost-effective-
ness analysis (CEA), 3) published in the past 10 years. Studies were assessed for 
the followings: country, model structure and simulation method, time horizon, 
perspective, source of key parameters, results, and key drivers determined from 
sensitivity analysis. Results: Six studies were reviewed in details. Markov (2 
articles) and discrete event simulation (2 articles) models were adopted, and 
transition probabilities among states were calculated from progress-free sur-
vival and overall survival obtained from clinical trials. Costs for chemotherapy 
were based on literature or expert opinion. Utility scores were assessed along 
with clinical trials (2 articles) or referred to other studies (3 articles). Inclusion of 
disutility of adverse events varied among studies. Parameters which became key 
drivers in those analyses were also different between studies. ConClusions: 
Data collection methods adopted in prior studies were applicable to CEA for MM 
treatment in Japan. Cost data can be obtained not only from questionnaire sur-
vey to doctors but commercial database. Because evidence on utility scores of 
Japanese population is still limited, further studies will be needed in Japanese 
patients.
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objeCtives: Colorectal cancer is the fourth most common cancer in the UK and 
the second most common cause of cancer death. NICE recommended the use of 
cetuximab for KRAS wild type mCRC patients with metastasis confined to the liver. 
Recent evidence demonstrated that cetuximab results in significant improvements 
in overall survival in patients with metastatic colorectal cancer (mCRC) expressing 
unmutated NRAS and KRAS exons (RAS wild type), when added to chemotherapy. To 
showcase the improved outcomes of cetuximab treatment and its cost effectiveness, 
a Cost-Utility Analysis was developed for an Health Technology Assessment evi-
dence submission to NICE. Methods: A de Novo Markov model was developed to 
assess the long term outcomes and cost effectiveness of adding cetuximab to either 
FOLFOX or FOLFIRI chemotherapy. The state transition model simulates patients’ 
journey through 5 health states: first, second and third line treatments post disease 
progression, successful surgical resection of liver metastasis with curative intent 
and death. The time horizon was set to 10 years and a 3.5% discount rate was applied 
to both outcomes and costs. Cetuximab list price was used in all analyses. Separate 
analyses were conducted using the licensed weekly cetuximab dose and the fort-
nightly dose typically used in clinical practice in England and Wales. Results: 
The model estimates that cetuximab addition to FOLFOX adds 0.32 QALYs and 0.29 
when added to FOLFIRI. When considering the fortnightly cetuximab dose, the ICER 
for combining cetuximab with FOLFOX is £46,503 per QALY compared to FOLFOX 
alone and £55,971 per QALY when combining cetuximab with FOLFIRI compared to 
FOLFIRI alone. ConClusions: The evidence submission to NICE demonstrated the 
significant improvements in overall survival (OS) in RAS wild type mCRC patients 
compared to standard treatments. The cost effectiveness of cetuximab could be 
deemed favourable especially when considering it as an “End of Life” medicine.
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objeCtives: Lung cancer is the cancer ranking top one in both incidence and mor-
tality among cancers in China. More than 85% of lung cancer patients suffer from 
non-small cell lung cancer (NSCLC). As the first epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor marketed in China, gefitinib was recommended as 
